ALGS logo

ALGS
Aligos Therapeutics Inc

1,229
Mkt Cap
$35.33M
Volume
127,783.00
52W High
$13.69
52W Low
$5.12
PE Ratio
-0.66
ALGS Fundamentals
Price
$5.77
Prev Close
$5.71
Open
$5.80
50D MA
$6.85
Beta
1.93
Avg. Volume
418,680.89
EPS (Annual)
-$2.45
P/B
1.11
Rev/Employee
$26,658.54
$19.42
Loading...
Loading...
News
all
press releases
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates
Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.read more...
News Placeholder
More News
News Placeholder
This Micro Cap Biotech Stock Is Tracking Its Biggest Intraday Gains In 11 Months – Here’s Why A China Deal Has Retail Buzzing
Aligos Therapeutics announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate in Greater China.
News Placeholder
Aligos Therapeutics Earnings Report: Q4 Overview
read more...
News Placeholder
A Peek at Aligos Therapeutics's Future Earnings
read more...
News Placeholder
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...
News Placeholder
Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
News Placeholder
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.
News Placeholder
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
News Placeholder
Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
News Placeholder
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available